BioCentury | Aug 28, 2017
Politics & Policy

FDA steps up enforcement, regulation of stem cell therapies

...not commercially available. Also on Monday, FDA published a warning letter it previously sent to U.S. Stem Cell Inc....
...from current good manufacturing practice and current good tissue practice." In the letter addressed to U.S. Stem Cell's...
...Century Cures Act (see BioCentury Extra, July 7) . Mary Romeo StemImmune Inc. U.S. Food and Drug Administration (FDA) U.S. Stem Cell Inc....
BioCentury | Dec 8, 2014
Financial News

Bioheart financial update

...Bioheart Inc. (OTCQB:BHRT), Sunrise, Fla. Business: Cardiovascular, Gene/Cell therapy Date announced: 2014-10-24 Note: Bioheart entered into...
BioCentury | Oct 13, 2014
Company News

Bioheart gene/cell therapy news

...Last month, Bioheart opened its South African Stem Cell Institute (SASCI) laboratory and clinic in South...
...received an in-clinic treatment and cell culture expansion and cryopreservation for future treatments as required. Bioheart...
BioCentury | Apr 28, 2014
Clinical News

AdipoCell: Clinical trial started

...open-label, U.S. clinical trial to evaluate IV AdipoCell in up to 100 patients with COPD. Bioheart...
...Bioheart rights to Invitrx's ADSC products for use in all indications in humans and animals. Bioheart...
...these techniques to advance the development and commercialization of AdipoCell (see BioCentury, Sept. 30, 2013). Bioheart...
BioCentury | Apr 14, 2014
Clinical News

AdipoCell: Clinical trial started

...I trial for congestive heart failure (CHF). Last year, Invitrx Therapeutics Inc. (Irvine, Calif.) granted Bioheart...
...to Invitrx's adipose-derived stem cell products for use in all indications in humans and animals. Bioheart...
...these techniques to advance the development and commercialization of AdipoCell (see BioCentury, Sept. 30, 2013). Bioheart...
BioCentury | Mar 24, 2014
Clinical News

AdipoCell: Additional Phase I data

...data will be presented at the Age Management Medicine Group meeting in Orlando in April. Bioheart...
...last September (see BioCentury, Oct. 14, 2013). Last year, Invitrx Therapeutics Inc. (Irvine, Calif.) granted Bioheart...
...Invitrx's adipose derived stem cell products for use in all indications in humans and animals. Bioheart...
BioCentury | Mar 24, 2014
Company News

Bioheart, Magnum Cell Therapies deal

...Bioheart's autologous cellular therapies to patients living in Honduras as well as to medical tourists. Bioheart...
...take a 10% ownership stake in Magnum. The companies could not be reached for details. Bioheart's...
...of blood vessels and healing. AdipoCell is in development to treat congestive heart failure (CHF). Bioheart...
BioCentury | Jan 27, 2014
Company News

Bioheart deal

...company said preclinical and veterinary clinical studies are underway and declined to provide further details. Bioheart...
BioCentury | Nov 11, 2013
Company News

Bioheart, Global Stem Cells Group Inc. sales and marketing update

...The companies partnered to provide Bioheart's therapies and products to Global Stem's network of physicians and...
...while contributing to the development and commercialization of Bioheart's products. Bioheart declined to disclose details. Bioheart's...
...vessels and healing that is in Phase I/II testing to treat congestive heart failure (CHF). Bioheart...
BioCentury | Oct 14, 2013
Clinical News

Adipose-derived stem cells: Preliminary Phase I data

...which Bioheart said is considered "clinically meaningful." Last month, Invitrx Therapeutics Inc. (Irvine, Calif.) granted Bioheart...
...Invitrx's adipose derived stem cell products for use in all indications in humans and animals. Bioheart...
...use these techniques to advance the development and commercialization of AdipoCell (see BioCentury, Sept. 30). Bioheart...
Items per page:
1 - 10 of 73
BioCentury | Aug 28, 2017
Politics & Policy

FDA steps up enforcement, regulation of stem cell therapies

...not commercially available. Also on Monday, FDA published a warning letter it previously sent to U.S. Stem Cell Inc....
...from current good manufacturing practice and current good tissue practice." In the letter addressed to U.S. Stem Cell's...
...Century Cures Act (see BioCentury Extra, July 7) . Mary Romeo StemImmune Inc. U.S. Food and Drug Administration (FDA) U.S. Stem Cell Inc....
BioCentury | Dec 8, 2014
Financial News

Bioheart financial update

...Bioheart Inc. (OTCQB:BHRT), Sunrise, Fla. Business: Cardiovascular, Gene/Cell therapy Date announced: 2014-10-24 Note: Bioheart entered into...
BioCentury | Oct 13, 2014
Company News

Bioheart gene/cell therapy news

...Last month, Bioheart opened its South African Stem Cell Institute (SASCI) laboratory and clinic in South...
...received an in-clinic treatment and cell culture expansion and cryopreservation for future treatments as required. Bioheart...
BioCentury | Apr 28, 2014
Clinical News

AdipoCell: Clinical trial started

...open-label, U.S. clinical trial to evaluate IV AdipoCell in up to 100 patients with COPD. Bioheart...
...Bioheart rights to Invitrx's ADSC products for use in all indications in humans and animals. Bioheart...
...these techniques to advance the development and commercialization of AdipoCell (see BioCentury, Sept. 30, 2013). Bioheart...
BioCentury | Apr 14, 2014
Clinical News

AdipoCell: Clinical trial started

...I trial for congestive heart failure (CHF). Last year, Invitrx Therapeutics Inc. (Irvine, Calif.) granted Bioheart...
...to Invitrx's adipose-derived stem cell products for use in all indications in humans and animals. Bioheart...
...these techniques to advance the development and commercialization of AdipoCell (see BioCentury, Sept. 30, 2013). Bioheart...
BioCentury | Mar 24, 2014
Clinical News

AdipoCell: Additional Phase I data

...data will be presented at the Age Management Medicine Group meeting in Orlando in April. Bioheart...
...last September (see BioCentury, Oct. 14, 2013). Last year, Invitrx Therapeutics Inc. (Irvine, Calif.) granted Bioheart...
...Invitrx's adipose derived stem cell products for use in all indications in humans and animals. Bioheart...
BioCentury | Mar 24, 2014
Company News

Bioheart, Magnum Cell Therapies deal

...Bioheart's autologous cellular therapies to patients living in Honduras as well as to medical tourists. Bioheart...
...take a 10% ownership stake in Magnum. The companies could not be reached for details. Bioheart's...
...of blood vessels and healing. AdipoCell is in development to treat congestive heart failure (CHF). Bioheart...
BioCentury | Jan 27, 2014
Company News

Bioheart deal

...company said preclinical and veterinary clinical studies are underway and declined to provide further details. Bioheart...
BioCentury | Nov 11, 2013
Company News

Bioheart, Global Stem Cells Group Inc. sales and marketing update

...The companies partnered to provide Bioheart's therapies and products to Global Stem's network of physicians and...
...while contributing to the development and commercialization of Bioheart's products. Bioheart declined to disclose details. Bioheart's...
...vessels and healing that is in Phase I/II testing to treat congestive heart failure (CHF). Bioheart...
BioCentury | Oct 14, 2013
Clinical News

Adipose-derived stem cells: Preliminary Phase I data

...which Bioheart said is considered "clinically meaningful." Last month, Invitrx Therapeutics Inc. (Irvine, Calif.) granted Bioheart...
...Invitrx's adipose derived stem cell products for use in all indications in humans and animals. Bioheart...
...use these techniques to advance the development and commercialization of AdipoCell (see BioCentury, Sept. 30). Bioheart...
Items per page:
1 - 10 of 73